Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Magnetic Resonance in Cancer Research
share announcement

Magnetic Resonance in Cancer Research

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Methods and Technologies Development".

Deadline for manuscript submissions: 15 August 2024 | Viewed by 1161

Special Issue Editors

Dr. Qiuhong He

E-Mail Website
Guest Editor
School of Health Sciences, Purdue University, West Lafayette, IN 47907, USA
Interests: magnetic resonance spectroscopic imaging technology for early detection of cancer treatment response; bacteria-based cancer therapy and imaging; cancer metastasis
Dr. Marie-France Vidaver

E-Mail Website
Guest Editor
Department of Radiology and Radiological Science, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA
Interests: applying magnetic resonance imaging and magnetic resonance spectroscopy to study the tumor microenvironment; early detection of ovarian cancer; cancer cachexia; theranostic imaging

Special Issue Information

Dear Colleagues,

Since Rabi’s first experiment on nuclear magnetic resonance (NMR) in 1938, magnetic resonance has become an indispensable medical imaging modality in cancer diagnosis and treatment monitoring. NMR-based metabolomics is now employed for tumor metabolic profiling to evaluate patients’ response to cancer treatment. NMR is also a powerful tool in structural biology. The structural characterization of protein interactions with small molecules has led to novel drug designs.  

We are pleased to invite you to contribute to this Special Issue of Cancers entitled ”Magnetic Resonance in Cancer Research”, focusing on cancer imaging for cancer diagnosis and treatment monitoring, as well as cellular and molecular imaging for precision medicine in order to improve patient outcomes. This Special Issue aims to collect research articles addressing magnetic resonance in cancer research, including pre-clinical studies and clinical investigations on all cancer types. 

In this Special Issue, original research articles and reviews are welcome. Research areas may include, but are not limited to, the following: (a) clinical MRI of cancer and machine learning; (b) diffusion-weighted MRI (DWI) in cancer treatment assessment; (c) fast proton MRSI in cancer biomarker detection; (d) MRI evaluation of cardiotoxicity of cancer therapy; (e) PET/MRI of cancer; (f) MR characterization of tumor oxygenation; (g) molecular imaging of cancer; (h) hyperpolarization C-13 MRS in cancer metabolic imaging; (i) deuterium MRS in cancer biomarker imaging; and (j) F-19 MRI in cancer drug metabolism and cell tracking, etc.

We look forward to receiving your contributions.

Dr. Qiuhong He
Dr. Marie-France Vidaver
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • magnetic resonance
  • cancer
  • MRI
  • MRS
  • MRSI
  • NMR
  • DWI
  • MR
  • molecular imaging

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

16 pages, 2581 KiB  
Article
Lonidamine Induced Selective Acidification and De-Energization of Prostate Cancer Xenografts: Enhanced Tumor Response to Radiation Therapy
by Stepan Orlovskiy, Pradeep Kumar Gupta, Jeffrey Roman, Fernando Arias-Mendoza, David S. Nelson, Cameron J. Koch, Vivek Narayan, Mary E. Putt and Kavindra Nath
Cancers 2024, 16(7), 1384; https://doi.org/10.3390/cancers16071384 - 31 Mar 2024
Viewed by 847
Abstract
Prostate cancer is a multi-focal disease that can be treated using surgery, radiation, androgen deprivation, and chemotherapy, depending on its presentation. Standard dose-escalated radiation therapy (RT) in the range of 70–80 Gray (GY) is a standard treatment option for prostate cancer. It could [...] Read more.
Prostate cancer is a multi-focal disease that can be treated using surgery, radiation, androgen deprivation, and chemotherapy, depending on its presentation. Standard dose-escalated radiation therapy (RT) in the range of 70–80 Gray (GY) is a standard treatment option for prostate cancer. It could be used at different phases of the disease (e.g., as the only primary treatment when the cancer is confined to the prostate gland, combined with other therapies, or as an adjuvant treatment after surgery). Unfortunately, RT for prostate cancer is associated with gastro-intestinal and genitourinary toxicity. We have previously reported that the metabolic modulator lonidamine (LND) produces cancer sensitization through tumor acidification and de-energization in diverse neoplasms. We hypothesized that LND could allow lower RT doses by producing the same effect in prostate cancer, thus reducing the detrimental side effects associated with RT. Using the Seahorse XFe96 and YSI 2300 Stat Plus analyzers, we corroborated the expected LND-induced intracellular acidification and de-energization of isolated human prostate cancer cells using the PC3 cell line. These results were substantiated by non-invasive 31P magnetic resonance spectroscopy (MRS), studying PC3 prostate cancer xenografts treated with LND (100 mg/kg, i.p.). In addition, we found that LND significantly increased tumor lactate levels in the xenografts using 1H MRS non-invasively. Subsequently, LND was combined with radiation therapy in a growth delay experiment, where we found that 150 µM LND followed by 4 GY RT produced a significant growth delay in PC3 prostate cancer xenografts, compared to either control, LND, or RT alone. We conclude that the metabolic modulator LND radio-sensitizes experimental prostate cancer models, allowing the use of lower radiation doses and diminishing the potential side effects of RT. These results suggest the possible clinical translation of LND as a radio-sensitizer in patients with prostate cancer. Full article
(This article belongs to the Special Issue Magnetic Resonance in Cancer Research)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop